Skip to main content

United Health Products Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

UEECStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 5. *Market information *

The common shares of the Company trade on the OTC Pink under the symbol UEEC. There is no established trading market for our common shares and there has been only limited trading activity to date. The following table sets forth the high and low sales price of the common stock on a quarterly basis for the periods presented, rounded to the nearest penny.

HighLow
First Quarter$0.30$0.19
Second Quarter$0.34$0.17
Third Quarter$0.34$0.23
Fourth Quarter$0.29$0.20
First Quarter$0.70$0.42
Second Quarter$0.79$0.35
Third Quarter$0.50$0.29
Fourth Quarter$0.33$0.21

Holders

As of April 1, 2024, there were approximately 401 holders of record of the Company’s issued and outstanding shares of common stock.

Dividends

The Company has not paid any dividends to date, has not yet generated earnings sufficient to pay dividends, and currently does not intend to pay dividends in the foreseeable future.

Stock Issuances and Repurchases

The following table summarizes all sales and issuances by the Company of unregistered securities during the year ended December 31, 2023. The securities in the below-referenced transactions were (i) issued without registration and (ii) were subject to restrictions under the Securities Act and the securities laws of certain states, in reliance on the private offering exemptions contained in Sections 4(a)(2), 4(a)(6) and/or 3(b) of the Securities Act and on Regulation D promulgated under the Securities Act, and in reliance on similar exemptions under applicable state laws as transactions not involving a public offering. No placement or underwriting fees were paid in connection with these transactions. All cash proceeds from the sale of securities were used for working capital and general corporate purposes.

Date of SaleTitle of SecurityNumber SoldConsiderationPurchaser/Recipient
January 2023Common Stock937,500$187,500 of accrued liabilitiesOfficers and consultants
January 2023Common Stock1,135,000$249,399 in cashWhite Lion (1)
February 2023Common Stock1,000,000$202,733 in cashWhite Lion (1)
March 2023Common Stock800,000$144,890 in cashWhite Lion (1)
March 2023Common Stock1,850,000$462,500 to settle litigationPhilip Forman
April 2023Common Stock979,688$156,750 of accrued liabilitiesOfficers and consultants
April 2023Common Stock450,000$86,524 in cashWhite Lion (1)
May 2023Common Stock800,000$139,797 in cashWhite Lion (1)
June 2023Common Stock2,300,000$589,506 in cashWhite Lion (1)
August 2023Common Stock500,000$123,035 in cashWhite Lion (1)
September 2023Common Stock530,000$124,358 in cashWhite Lion (1)
October 2023Common Stock480,000$112,334 in cashWhite Lion (1)
November 2023Common Stock650,000$156,501 in cashWhite Lion (1)
December 2023Common Stock1,500,000$329,046 in cashWhite Lion (1)
(1)Issued by the Company to White Lion Capital, LLC pursuant to the terms of the Common Stock Purchase Agreement dated September 1, 2022, as amended January 25, 2023.

Description of Our Capital Stock

The following description of our capital stock is a summary only and is qualified by reference to our Certificate of Incorporation and Bylaws, which are included as Exhibits 3.1, 3.2, 3.3 and 3.4 to this report.

General

Our authorized capital stock consists of 300,000,000 shares of common stock, with a par value of $0.001 per share. As of April 1, 2024, there were 246,833,222 shares of common stock issued and outstanding.

Common Stock

Each holder of Common Stock will be entitled to one vote for each share of Common Stock held of record by such holder with respect to all matters to be voted on or consented to by our stockholders, except as may otherwise be required by applicable Nevada law. The stockholders will not have pre-emptive rights under our Certificate of Incorporation to acquire additional shares of Common Stock or other securities. The Common Stock will not be subject to redemption rights and will carry no subscription or conversion rights. In the event of liquidation of the Company, the stockholders will be entitled to share in corporate assets on a pro rata basis after the Company satisfies all liabilities and after provision is made for each class of capital stock having preference over the Common Stock (if any). Subject to the laws of the State of Nevada, and the rights of the holders of any outstanding series of preferred stock (if any), the Board of Directors will determine, in their discretion, to declare dividends advisable and payable to the holders of outstanding shares of Common Stock.

Transfer Agent and Registrar

Pacific Stock Transfer Company is the registrar and transfer agent for our shares of common stock. Its address is 6725 Via Austi Pkwy, Suite 300, Las Vegas, NV 89119, United States; Telephone: (800) 785-7782.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.